The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis
Open accessAbstract
We report the efficient identification of four human histocompatibility leukocyte antigen (HLA)-A*0201–presented cytotoxic T lymphocyte (CTL) epitopes in the tumor-associated antigen PRAME using an improved “reverse immunology” strategy. Next to motif-based HLA-A*0201 binding prediction and actual binding and stability assays, analysis of in vitro proteasome-mediated digestions of polypeptides encompassing candidate epitopes was incorporated in the epitope prediction procedure. Proteasome cleavage pattern analysis, in particular determination of correct COOH-terminal cleavage of the putative epitope, allows a far more accurate and selective prediction of CTL epitopes. Only 4 of 19 high affinity HLA-A*0201 binding peptides (21%) were found to be efficiently generated by the proteasome in vitro. This approach avoids laborious CTL response inductions against high affinity binding peptides that are not processed and limits the number of peptides to be assayed for binding. CTL clones induced against the four identified epitopes (VLDGLDVLL, PRA100–108; SLYSFPEPEA, PRA142–151; ALYVDSLFFL, PRA300–309; and SLLQHLIGL, PRA425–433) lysed melanoma, renal cell carcinoma, lung carcinoma, and mammary carcinoma cell lines expressing PRAME and HLA-A*0201. This indicates that these epitopes are expressed on cancer cells of diverse histologic origin, making them attractive targets for immunotherapy of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sallusto, F., & Lanzavecchia, A. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.4.1109 · Cited by 5,129
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862 · cited 2×
“(3) IC50 (in mM) as determined in competition binding assay (see Table I); (4) start and end aa position in PRAME of 27-mer polypeptide encompassing the high affinity binding peptide; (5) aa sequence of 27-mer polypeptide (aa sequence of HLA-A*0201 binding peptide is printed in bold and shaded); (6) major (bold arrows…”
BackgroundMethodCella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., & Alber, G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.747 · Cited by 1,983
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
Parker, K. C., Bednarek, M. A., & Coligan, J. E. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.1.163 · Cited by 1,370
Thurner, B., Haendle, I., Röder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1669 · Cited by 1,226
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3515 · Cited by 1,092
MECHANISMS OF MHC CLASS I–RESTRICTED ANTIGEN PROCESSING
Pamer, E., & Cresswell, P. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.323 · Cited by 1,008
Brichard, V, Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethé, B., Coulie, P., & Boon, T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.489 · Cited by 950
IMMUNODOMINANCE IN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I–RESTRICTED T LYMPHOCYTE RESPONSES
Yewdell, J. W., & Bennink, J. R. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.51 · Cited by 944
Coulie, P. G., Brichard, V, Van Pel, A., Wölfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.35 · Cited by 903
Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dr�no, B., Tessier, M.-H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s · Cited by 784
Ikeda, H., Lethé, B., Lehmann, F., Van Baren, N., Baurain, J.-F., De Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80426-4 · Cited by 762
Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., Van Pel, A., De Plaen, E., Amar-Costesec, A., & Boon, T. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.5.1453 · Cited by 679
Van den Eynde, B. J., & van der Bruggen, P. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80050-7 · Cited by 623
ANTIGEN PROCESSING AND PRESENTATION BY THE CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX
York, I. A., & Rock, K. L. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.369 · Cited by 610
Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., & Figdor, C. G. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.1005 · Cited by 589
BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
Boël, P., Wildmann, C., Sensi, M. L., Brasseur, R., Renauld, J.-C., Coulie, P., Boon, T., & van der Bruggen, P. (1995) · Immunity · doi:10.1016/s1074-7613(95)80053-0 · Cited by 583
Van den Eynde, B., Peeters, O., De Backer, O., Gaugler, B., Lucas, S., & Boon, T. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.3.689 · Cited by 567
A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens
Rosenberg, S. A. (1999) · Immunity · doi:10.1016/s1074-7613(00)80028-x · Cited by 566
The major substrates for TAP in vivo are derived from newly synthesized proteins
Reits, E. A. J., Vos, J. C., Grommé, M., & Neefjes, J. (2000) · Nature · doi:10.1038/35008103 · Cited by 415
Morel, S., Lévy, F., Burlet-Schiltz, O., Brasseur, F., Probst-Kepper, M., Peitrequin, A.-L., Monsarrat, B., Van Velthoven, R., Cerottini, J.-C., Boon, T., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)80163-6 · Cited by 415
van der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M., & Melief, C. J. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.9.3308 · Cited by 394
Self-citationFas ligation induces apoptosis of CD40-activated human B lymphocytes.
Garrone, P., Neidhardt, E. M., Garcia, E., Galibert, L., van Kooten, C., & Banchereau, J. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1265 · Cited by 390
van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P. G., Boël, P., De Smet, C., Traversari, C., Townsend, A., & Boon, T. (1994) · European Journal of Immunology · doi:10.1002/eji.1830241218 · Cited by 367
Schultze, J. L., Michalak, S., Seamon, M. J., Dranoff, G., Jung, K., Daley, J., Delgado, J. C., Gribben, J. G., & Nadler, L. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119822 · Cited by 355
MHC Ligands and Peptide Motifs
Rammensee, H.-G., Bachmann, J., & Stevanović, S. (1997) · Molecular Biology Intelligence Unit · doi:10.1007/978-3-662-22162-4 · Cited by 331
Boes, B., Hengel, H., Ruppert, T., Multhaup, G., Koszinowski, U. H., & Kloetzel, P. M. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.901 · Cited by 319
Celis, E., Tsai, V, Crimi, C., DeMars, R., Wentworth, P. A., Chesnut, R. W., Grey, H. M., Sette, A., & Serra, H. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2105 · Cited by 306
Beninga, J., Rock, K. L., & Goldberg, A. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.30.18734 · Cited by 296
Craiu, A., Akopian, T., Goldberg, A., & Rock, K. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10850 · Cited by 264
Kawashima, I., Hudson, S. J., Tsai, V., Southwood, S., Takesako, K., Appella, E., Sette, A., & Celis, E. (1998) · Human Immunology · doi:10.1016/s0198-8859(97)00255-3 · Cited by 229
Groettrup, M., Ruppert, T., Kuehn, L., Seeger, M., Standera, S., Koszinowski, U., & Kloetzel, P. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23808 · Cited by 228
Niedermann, G., Butz, S., Ihlenfeldt, H. G., Grimm, R., Lucchlarl, M., Hoschotzky, H., Jung, G., Maier, B., & Elchmann, K. (1995) · Immunity · doi:10.1016/1074-7613(95)90053-5 · Cited by 225
Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes
Vierboom, M. P. M., Nijman, H. W., Offringa, R., Voort, E. I. H. V. D., Hall, T. V., Broek, L. V. D., Fleuren, G. J., Kenemans, P., Kast, W. M., & Melief, C. J. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.695 · Cited by 206
Self-citationParkhurst, M. R., Fitzgerald, E., Southwood, S., Sette, A., Rosenberg, S. A., & Kawakami, Y. (1998) · PubMed · Cited by 192
Baren, V., Chambost, Ferrant, Michaux, Ikeda, Millard, Olive, Boon, & Coulie (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00982.x · Cited by 183
Sijts, A. J. A. M., Ruppert, T., Rehermann, B., Schmidt, M., Koszinowski, U. H., & Kloetzel, P. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.3.503 · Cited by 183
Self-citationDick, L. R., Aldrich, C., Jameson, S. C., Moomaw, C. R., Pramanik, B. C., Doyle, C. K., DeMartino, G. N., Bevan, M. J., Forman, J. M., & Slaughter, C. A. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.8.3884 · Cited by 183
Ossendorp, F., Eggers, M., Neisig, A., Ruppert, T., Groettrup, M., Sijts, A., Mengedé, E., Kloetzel, P.-M., Neefjes, J., Koszinowski, U., et al. (1996) · Immunity · doi:10.1016/s1074-7613(00)80488-4 · Cited by 179
Self-citationTsai, V, Southwood, S., Sidney, J., Sakaguchi, K., Kawakami, Y., Appella, E., Sette, A., & Celis, E. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.4.1796 · Cited by 175
Bertoletti, A., Chisari, F. V., Penna, A., Guilhot, S., Galati, L., Missale, G., Fowler, P., Schlicht, H. J., Vitiello, A., & Chesnut, R. C. (1993) · Journal of Virology · doi:10.1128/jvi.67.4.2376-2380.1993 · Cited by 173
Strategies for immunotherapy of cancer
Melief, C. J. M., Toes, R. M., Medema, J. P., Van Der Burg, S. H., Ossendorp, F., & Offringa, R. (2000) · Advances in Immunology · doi:10.1016/s0065-2776(00)75006-1 · Cited by 165
Self-citationDistinct Proteolytic Processes Generate the C and N Termini of MHC Class I-Binding Peptides
Mo, X. Y., Cascio, P., Lemerise, K., Goldberg, A. L., & Rock, K. L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.11.5851 · Cited by 161
Chaux, P., Luiten, R. M., Demotte, N., Vantomme, V., Stroobant, V., Traversari, C., Russo, V. E. A., Schultz, E. S., Cornelis, G. R., Boon, T., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.5.2928 · Cited by 156
An algorithm for the prediction of proteasomal cleavages
Kuttler, C., Nussbaum, A. K., Dick, T. P., Rammensee, H., Schild, H., & Hadeler, K.-P. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3683 · Cited by 155
Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum.
Elliott, T. J., Willis, A. E., Cerundolo, V., & Townsend, A. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.4.1481 · Cited by 153
Roelse, J., Grommé, M., Momburg, F., Hämmerling, G. J., & Neefjes, J. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.5.1591 · Cited by 153
Disis, M. L., Smith, J. W., Murphy, A. E., Chen, W., & Cheever, M. A. (1994) · PubMed · Cited by 148
Schwarz, K., van den Broek, M. F., Kostka, S., Kraft, R., Soza, A., Schmidtke, G., Kloetzel, P., & Groettrup, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.2.768 · Cited by 146
van Hall, T., Sijts, A. J. A. M., Camps, M. G. M., Offringa, R., Melief, C. J. M., Kloetzel, P., & OSSENDORP, F. A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.483 · Cited by 136
Self-citationSijts, A. J. A. M., Standera, S., Toes, R. E. M., Ruppert, T., Beekman, N. J. C. M., van Veelen, P. A., OSSENDORP, F. A., Melief, C. J. M., & Kloetzel, P. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4500 · Cited by 117
Self-citationBeekman, N. J. C. M., van Veelen, P. A., van Hall, T., Neisig, A., Sijts, A. J. A. M., Camps, M. G. M., Kloetzel, P., Neefjes, J., Melief, C. J. M., & OSSENDORP, F. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.1898 · Cited by 107
Self-citationHerman, J., van der Bruggen, P., Luescher, I. F., Mandruzzato, S., Romero, P. J., Thonnard, J., Fleischhauer, K., Boon, T., & Coulie, P. G. (1996) · Immunogenetics · doi:10.1007/bf02199806 · Cited by 104
Design and evaluation of antigen-specific vaccination strategies against cancer
Offringa, R., van der Burg, S. H., OSSENDORP, F. A., Toes, R. E. M., & Melief, C. J. M. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00145-x · Cited by 97
Self-citationvan der Burg, S. H., Ras, E., Drijfhout, J. W., Benckhuijsen, W. E., Bremers, A. J. A., Melief, C. J. M., & Kast, W. M. (1995) · Human Immunology · doi:10.1016/0198-8859(95)00105-0 · Cited by 90
Self-citationD'Amaro, J., Houbiers, J. G. A., Drijfhout, J. W., Brandt, R. M. P., Schipper, R. F., Bavinck, J. N. B., Melief, C. J. M., & Kast, W. M. (1995) · Human Immunology · doi:10.1016/0198-8859(94)00153-h · Cited by 87
Self-citationp53, a potential target for tumor-directed T cells
Nijman, H. W., van der Burg, S. H., Vicrboom, M. P. M., Houbiers, J. G. A., Kast, W. M., & Melief, C. J. M. (1994) · Immunology Letters · doi:10.1016/0165-2478(94)90189-9 · Cited by 86
Self-citationvan Elsas, A., Nijman, H. W., van der Minne, C. E., Mourer, J. S., Kast, W. M., Melief, C. J. M., & Schrier, P. I. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610319 · Cited by 83
Self-citationGedde‐Dahl, T., Spurkland, A., Fossum, B., Thorsby, E., Gaudernack, G., & Wittinghofer, A. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240221 · Cited by 31
van de Corput, L., Kluin‐Nelemans, H. C., Kester, M. G. D., et al. (1999) · Blood · doi:10.1182/blood.v93.1.251 · Cited by 17
Self-citation
Cited by
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Self-citationWallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
A listing of human tumor antigens recognized by T cells
Renkvist, N., Castelli, C., Robbins, P. F., & Parmiani, G. (2001) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620000169 · Cited by 694
HUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
A listing of human tumor antigens recognized by T cells: March 2004 update
Novellino, L., Castelli, C., & Parmiani, G. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0560-6 · Cited by 466
Metadata
- Authors
- Kessler, J. H., Beekman, N. J., Bres-Vloemans, S. A., Verdijk, P., van Veelen, P. A., Kloosterman-Joosten, A. M., Vissers, D. C. J., ten Bosch, G. J. A., Kester, M. G. D., Sijts, A., Drijfhout, J. W., Ossendorp, F., Offringa, R., & Melief, C. J. M.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2001-01-01
- Volume
- 193
- Issue
- 1
- Pages
- 73-88
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2132925083
- Cited by
- 263
- References
- 62
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.